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Matthew A. Romano, MD, Jonathan Haft, MD, and Francis D. Pagani, MD, PhDCardiac transplantation is still considered the goldstandard for treatment of advanced heart failure
refractory to medical therapy. More than 16 million people
suffer from heart failure (HF) in the United States and
Europe. Its prevalence is estimated to be 2.5% of the
population and increases considerably after 65 years of age.
The limiting factor to treating advanced HF with cardiac
transplantation remains the lack of suitable donors. The
development and use of ventricular assist devices (VADs) has
become an important therapy in treating refractory HF.
Approximately one-fourth of all patients undergoing trans-
plantation in the United States have been supported with
these VADs. Furthermore, the use of these devices as
permanent or destination therapy is increasing rapidly.
The ﬁrst-generation left VADs (LVADs) were pulsatile-
ﬂow devices. These pumps were large-sized devices
necessitating extensive surgical dissection and were not
suitable for smaller-sized patients. Although these devices
provided excellent support, they lacked long-term durability
owing to bearing wear. Second-generation pumps repre-
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.edupulsatile-ﬂow devices. Second-generation devices had a
continuous-ﬂow axial design pump that offered virtually
noiseless operation with improved durability, thereby
resulting in improved long-term survival. Additionally, the
smaller size of these pumps limits the surgical dissection
required for implantation and allows for a wider application
in smaller women and children. The HeartWare HVAD
(HeartWare International Inc, Framingham, MA) is a third-
generation LVAD that is a continuous-ﬂow centrifugal pump
with an integrated inﬂow cannula. The HVAD has only
1 moving part and no mechanical bearings. The wide-blade
impeller is levitated by a hybrid passive magnet and
hydrodynamic ﬂuid forces. It is able to generate an output
of 10 L/min and operates at pump speeds between 2400 rpm
and 3200 rpm. It is a small pump with a displacement of
50 cc and weighs 140 g, which facilitates implantation and is
intended for intrapericardial placement. Communication
from the pump to the control and power components is
provided by an externalized, ﬂexible polyurethane-covered
driveline. A continuous power supply is provided by the AC
wall power or lithium-ion batteries for portable use. The
HVAD has been approved for use as a bridge to trans-
plantation, and it is currently in trial for evaluation for
destination therapy indication. This article describes the
implantation technique for the HeartWare HVAD. (Figs. 1-6)
Figure 1 Patient and surgical preparation. Patients with advanced HF are preoperatively maintained with inotrope infusions to optimize organ
function. To minimize infectious risks, a new central venous pulmonary artery (PA) catheter should be inserted no more than 24 hours
preoperatively. The routine use of PA catheters for LVAD implantation may assist with perioperative therapies including pulmonary
vasodilator therapy with nitric oxide as well as inotropic and vasoconstrictor support. The general preparation is similar to other cardiac
surgical procedures with the patient prepared and draped in the standard sterile fashion. Routine broad-spectrum antibiotics are administered
intravenously. In addition to the PA catheter, an arterial line and a Foley catheter are inserted. A transesophageal echocardiogram (TEE) is used
to assess for a patent foramen ovale, valvular dysfunction, and intracardiac thrombi before implantation and is used to optimize pump speed
while weaning from cardiopulmonary bypass following implantation. A standard median sternotomy is performed and the pericardium is
incised; this incision is carried to the left, along the pericardial reﬂection to the apex. Ao ¼ aorta.
Operative Technique
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Figure 2 Preparation of the driveline exit site before administration of heparin. We routinely exit the driveline along the anterior axillary line,
approximately 2 cm below the costal margin on the right side. Using the tunneling device, the driveline is tunneled through the rectus muscle.
The woven polyester portion of the driveline should be completely housed in the subcutaneous tissue 1-2 cm from the skin exit site. The
pump and driveline are temporarily wrapped in an antibiotic-soaked laparotomy pad.
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Figure 3 Cannulation. The patient is systemically heparinized. Cannulation for cardiopulmonary bypass is accomplished with an arterial
cannula in the distal ascending aorta or proximal aortic arch. It is important to leave enough length on the aorta for a deairing cannula and
positioning of the outﬂow graft. A 2-stage venous return cannula is used for venous return. Bicaval cannulation is used if closure of a patent
foramen ovale or tricuspid valve repair or replacement is performed concomitant with LVAD implant. LAD ¼ left anterior descending; Ao ¼
aorta; PA ¼ pulmonary artery.
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Figure 4 Placement of the inﬂow cannula. The procedure is performed on full cardiopulmonary bypass on the beating heart. The heart is
elevated and supported with moist laparotomy pads to expose the left ventricle (LV) and apex. Correct positioning of the inﬂow cannula is
essential. It should be parallel to the interventricular septum and directed toward the mitral valve. To achieve this, the sewing ring is attached to
the distal anterior surface of the LV, approximately 2 cm lateral to the left anterior descending artery. (A) We place 12, 2-0 ETHIBOND
pledgeted sutures deep in the myocardium and then through the Dacron sewing ring. It is recommended that the integrated screw of the sewing
ring be oriented parallel to the LAD and pointing toward the base of the heart to facilitate tightening. (B) Once the sewing ring is seated, all
sutures are tied down. (C) A full-thickness cruciate incision is made in the myocardium within the middle of the sewing ring. (D) The
myocardium within the ring is then excised with the punch device supplied by HeartWare. The LV is then inspected for thrombus and crossing
trabeculae, which are excised as necessary.
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Figure 4 (Continued) (E) At this point, it is our practice to infuse CO2 into the LV cavity to facilitate deairing of the LV. (F) The inﬂow cannula is
then inserted into the sewing ring and the device is positioned with the outﬂow graft and driveline parallel to the diaphragm, and the screw on
the sewing ring is tightened. Additional deairing is accomplished by passively ﬁlling the heart and pump and elevating the apex and gently
shaking the ventricle. (G) The outﬂow graft is then distended, clamped, and trimmed to proper length.
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Figure 5 Outﬂow graft anastomosis. It is crucial to determine the appropriate length of the outﬂow graft as excess length may lead to kinking of
the graft. Conversely, a short graft may cause added tension to the anastomosis and lead to bleeding or obstruction. The outﬂow graft should
lie along the right atrium. (A) The anastomosis is performed along the proximal anterolateral ascending aorta. A partial-occlusion clamp is
placed without dissecting the plane between the aorta and PA. The aorta is incised and the anastomosis is sewn with a 4-0 polypropylene
suture. Pledgets are usually not necessary for this anastomosis. The anastomosis is deaired. The partial-occlusion clamp is then removed to
assess hemostasis. A vascular clamp should remain on the outﬂow graft while the device is off to avoid retrograde ﬂow into the aorta. (B) A
deairing cannula is placed in the ascending left ventricle between the outﬂow graft and aortic cannula. It is important to place the graft as
proximal as possible to allow for future cannulation and aortic anastomosis at the time of heart transplantation.
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Figure 6 Deairing and weaning from cardiopulmonary bypass and closure. In addition to the deairing cannula in the ascending aorta, the patient is
placed in the Trendelenburg position and ventilation is resumed. The device driveline is connected to the controller. At this point, administration of
nitric oxide is started as well as a combination of vasopressor and inotropic support to assist the right heart. (A) The patient is then gradually weaned
from cardiopulmonary bypass. Once ﬂow is less than 2 L/min, the vascular clamp on the outﬂow graft is removed and the HVAD is started at
1800 rpm and increased as cardiopulmonary bypass is terminated. The increase in speed should be in increments no greater than 100 rpm with a 20-
second interval between speed changes to gradually increase ﬂow and help prevent ventricular collapse. To optimize and set pump speed, the TEE is
used to visualize the position of the interventricular septum, size of the LV, and intermittent opening of the aortic valve. The recommended operating
speed is 2400-3200 rpm. The ﬂow trough should be more than 2 L/min and a target ﬂow pulsatility of 2-4 L/min, as measured from peak to trough
of the ﬂow waveform on the device monitor, is desired. Once deairing is conﬁrmed by TEE, the vent cannula in the ascending aorta is removed.
When the hemodynamics is appropriate, protamine is administered and the cannulae are removed. (B) To minimize adhesions and facilitate
reoperation at the time of transplantation, we wrap the outﬂow graft with a GORE-TEX pericardial membrane secured with a 4-0 polypropylene
suture. (C) Additionally, a piece of GORE-TEX membrane is sewn to either side of the pericardium to cover the heart and device. (D) Mediastinal
chest tubes are inserted and the chest is closed in the standard fashion. The driveline is secured at the skin edge with a 5-0 polypropylene purse-string
suture and a 2-0 polypropylene stitch is used to secure the driveline to the abdominal wall approximately 5 cm from the exit site to prevent accidental
dislodgement in the early postoperative period.
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The patients are weaned off inotropes, vasoconstrictors, and
nitric oxide over the 24-48 hours following implantation. Pump
speed may vary during this weaning period to optimize
hemodynamics and treat suction events. One may consider
obtaining a transthoracic echocardiogram to assist in setting the
HVAD rpm to ensure appropriate interventricular septal
position and appropriate LV unloading. Systemic antimicrobial
prophylaxis is continued for 48 hours. Once prophylactic
antibiotics are discontinued, broad-spectrum antimicrobials are
started until the chest tubes have been removed and drainage
from the driveline site has stopped. Anticoagulation should be
individualized for each patient. Chest tube drainage should be
less than 40 mL/h for at least 3 hours and the hematocrit
should be stable without the need for transfusion of blood
products. In general, low-dose heparin infusion of 400-500
units/h is begun on postoperative day 1 to a target partial
thromboplastin time of 40-50 seconds. The heparin dose is
gradually increased to maintain a partial thromboplastin time in
the range of 50-60 seconds. Warfarin administration is theninitiated and titrated to maintain the international normalized
ratio at 2.0-3.0; additionally, aspirin 325 mg is initiated on
postoperative day 1. Dual antiplatelet therapy with dipyrida-
mole, for example, may be considered to compliment the
anticoagulation regimen.
Summary
As the use of LVADs to treat advanced HF continues to
increase and the technology advances, LVADs will continue to
evolve into smaller and more efﬁcient pumps. The small size
of the HeartWare HVAD enables positioning in the pericardial
space, thereby minimizing the need for extensive dissection.
The unique integrated screw mechanism of the sewing ring
simpliﬁes attachment to the inﬂow cannula. Additionally, the
small size of the device permits application to patients with a
small body habitus. The absence of contact bearings with a
single magnetically and hydrodynamically levitated moving
part may improve long-term durability and efﬁciency. As our
population ages and the need for assist devices increases,
implantation of LVADs will continue to increase.
